Vaxart, Inc. 8-K

What Happened

• On July 1, 2026 Vaxart, Inc. entered into a Cooperation Agreement with a Stockholder Group (Daniel P. Houle; Dr. Mark Silverberg; Dr. Matthew M. Wallace; Patrice Raffy; Q3 Nominees Pty Ltd.; and Marc Eustace Pereira). The group withdrew its notice nominating three director candidates for the 2026 Annual Meeting and withdrew a books-and-records demand.
• The parties agreed to work together for a period following the 2026 Annual Meeting to identify and appoint one mutually agreed independent director (the “New Director”), who will join the Nominating and Corporate Governance Committee and may be considered for additional committee assignments. The agreement includes customary voting commitments, a standstill, and non‑disparagement provisions, and requires the Company to meet with the Stockholder Group at least quarterly (post‑earnings) during the agreement term.

Key Details

• Date of agreement: July 1, 2026; disclosed in an 8‑K filed July 2, 2026.
• Governance changes to be adopted after the 2026 Annual Meeting include: a resignation policy for directors receiving less than majority support in uncontested elections, stock ownership guidelines for directors, creation of a Clinical and Regulatory Affairs Committee (to be chaired by James B. Breitmeyer), and formation of a Stockholder Engagement Committee (to be chaired by the New Director).
• The Company agreed to reimburse the Stockholder Group for reasonable documented out‑of‑pocket fees and expenses related to its engagement and solicitation efforts, capped at $650,000.
• Termination: the Cooperation Agreement generally ends the earlier of (x) 30 days before the nomination deadline for the 2027 annual meeting or (y) 75 days before the first anniversary of the 2026 Annual Meeting, with an automatic delay mechanism tied to renomination of the New Director.

Why It Matters

• For investors, the agreement reduces the immediate risk of a contested proxy fight by formalizing cooperation between Vaxart and the activist group and by providing for the appointment of an independent director.
• The specified governance changes (resignation policy, ownership guidelines, and new committees focused on clinical/regulatory affairs and stockholder engagement) could increase board oversight of clinical and regulatory strategy and improve investor communication.
• The expense reimbursement cap ($650,000) and the standstill/voting commitments define the scope and timeline of the activist engagement, which limits near‑term activist actions but preserves investor visibility into future board composition.